Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 1—January 2015
Synopsis

Tularemia in Children, Turkey, September 2009–November 2012

Hasan Tezer, Aslınur Ozkaya-ParlakayComments to Author , Hakan Aykan, Mustafa Erkocoglu, Belgin Gülhan, Ahmet Demir, Saliha Kanik-Yuksek, Anil Tapisiz, Meltem Polat, Soner Kara, Ilker Devrim, and Selcuk Kilic
Author affiliations: Gazi University School of Medicine, Ankara, Turkey (H. Tezer, A. Tapisiz, M. Polat, S. Kara); Ankara Hematology Oncology Children’s Training and Research Hospital, Ankara (A. Ozkaya-Parlakay, H. Aykan, M. Erkocoglu, B. Gülhan, A. Demir, S. Kanik-Yuksek); Dr. Behcet Uz Children's Training and Research Hospital, Izmir, Turkey (I. Devrim); Public Health Institution of Turkey, Ankara (S. Kilic)

Main Article

Table 3

Results of regression analysis for variables predicting treatment outcomes for 100 children with tularemia, Ankara, Turkey, September 2009–November 2012*

OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Female sex 3.449
(1.250–9.514) 0.017 1.348
(0.313–5.804) 0.689 2.314
(0.850–6.300) 0.101 1.842
(0.716–4.742) 0.205
Treatment delay >16 d
3.277
(1.220–8.799)
0.019

6.074
(1.185–31.131)
0.030

1.295
(0.477–3.517)
0.612

1.876
(0.741–4.751)
0.184
Antimicrobial drug
GEN† 0.067 ND ND 0.643 0.140
DOX 4.965
(1.280–19.264) 0.021 ND ND 1.295
(0.355–4.733) 0.695 3.308
(0.957–11.428) 0.059
CIP 2.637
(0.733–9.483) 0.138 ND ND 0.542
(0.124–2.371) 0.416 2.689
(0.808–8.950) 0.107
GEN + DOX
0.458
(0.060–3.473)
0.450

ND
ND

0.376
(0.035–4.033)
0.419

0.636
(0.094–4.317)
0.643
Age at diagnosis 0.926
(0.832–1.031) 0.162 0.941
(0.755–1.173) 0.589 0.925
(0.801–1.067) 0.283 0.935
(0.841–1.041) 0.219
Age at study inclusion 2.611
(0.739–9.222) 0.136 2.096
(0.151–29.018) 0.581 2.588
(0.476–14.086) 0.271 2.321
(0.658–8.183) 0.190

*Because the number of patients was limited, antimicrobial drugs were not included in the regression analysis for spontaneous suppuration. CIP, ciprofloxacin; DOX, doxycycline; GEN, gentamicin; ND, not done.
†Reference variable.

Main Article

Page created: December 17, 2014
Page updated: December 17, 2014
Page reviewed: December 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external